News

Pharmetheus presence at ISTH 2020 congress

Pharmetheus colleagues are co-authors to 4 abstracts to be presented at the virtual International Society on Thrombosis and Haemostasis Congress 12-14 July 2020.

Read more about our support to drug development of a recombinant von Willebrand factor in patients with severe von Willebrand disease (abstract numbers PB1541 and PB1544) and of dabigatran in children with venous thromboembolism (abstract numbers PB1271 and PB1272): https://www.isth2020.org/abstracts

Read More »

New service: Quantitative Systems Pharmacology (QSP)

Physiologically based pharmacokinetic (PBPK) modelling is a technique to predict drug concentration at the site of pharmacological action. It appears natural to combine PBPK models with quantitative systems pharmacology (QSP) models to get a mechanistic understanding of the PK/PD relationship(s) of the drug in patients.

PBPK-QSP models build on prior knowledge, including (patho-)physiology and pharmacology. The independent representations of drug and system parameters allow for extrapolation to scenarios beyond observation. The methodology can enhance drug development programs by informing biomarker strategies and early prediction of clinical outcome. Read more about PBPK-QSP here.

Read More »

Welcome Henrik Hellerstedt!

We are happy to welcome Henrik Hellerstedt in our growing IT team. Henrik has worked as a senior IT consultant and has experience as an IT manager in both public and large private entities. Henrik will be working as an IT system administrator and will be based in the Uppsala Office. Glad to have you onboard, Henrik!

Read More »

Pharmetheus Approach to COVID-19 related challenges in clinical trial conduct

Pharmetheus is currently working with a number of clients to address the impact of the current COVID-19 epidemic to their ongoing clinical drug development programs. We would like to share our high level approach with the community at large. We see the current situation as both a challenge to our industry/sector but also an opportunity for appropriate and quantitative approaches to mitigate upon these challenges. We believe there are “fit for purpose” options for a broad range of plausible scenarios in clinical trial conduct that have emerged or could emerge.

See our approach

Read More »